InsiderTrades.com logo
The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way
From Smallcaps Daily   |   Ad
See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
Click to read

KRRO Insider Trading

Insider Ownership Percentage: 16.80%
Insider Buying (Last 12 Months): $999,992.00
Insider Selling (Last 12 Months): $43,569.64

Korro Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Korro Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Korro Bio Share Price & Price History

Current Price: $52.32
Price Change: ▼ Price Decrease of -1.69 (-3.13%)
As of 05/8/2024 05:00 PM ET

This chart shows the closing price history over time for KRRO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way
From Smallcaps Daily   |   Ad
See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
Click to read

Korro Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/22/2024Venture Opportunity Fund AtlasMajor ShareholderBuy17,857$56.00$999,992.00195,074View SEC Filing Icon  
11/22/2023David L LucchinoDirectorSell1,156$37.69$43,569.6422,150View SEC Filing Icon  
See Full Table
The Weight Loss Pill That Could Disrupt a $32 Billion Industry
From Behind the Markets   |   Ad
A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.
Don't miss out on the "next Ozempic" >>>

SEC Filings (Institutional Ownership Changes) for Korro Bio (NASDAQ:KRRO)

13.18% of Korro Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KRRO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Korro Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/20/2024Eventide Asset Management LLC546,325$26.19M0.4%N/A73.828%Search for SEC Filing on Google Icon
2/14/202472 Investment Holdings LLC276,831$13.27M58.9%N/A37.410%Search for SEC Filing on Google Icon
2/12/2024Monashee Investment Management LLC90,805$4.35M0.8%N/A12.271%Search for SEC Filing on Google Icon
2/9/2024Atlas Venture Life Science Advisors LLC1,119,292$53.65M6.4%N/A151.256%Search for SEC Filing on Google Icon
1/10/2024North Star Investment Management Corp.1,000$48K0.0%N/A0.135%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Korro Bio logo
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Read More on Korro Bio

Today's Range

Now: $52.32
Low: $51.42
High: $53.35

50 Day Range

MA: $65.62
Low: $46.95
High: $90.00

52 Week Range

Now: $52.32
Low: $9.15
High: $97.91

Volume

42,912 shs

Average Volume

28,532 shs

Market Capitalization

$419.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28

Who are the company insiders with the largest holdings of Korro Bio?

Korro Bio's top insider investors include:
  1. Venture Opportunity Fund Atlas (Major Shareholder)
  2. David L Lucchino (Director)
Learn More about top insider investors at Korro Bio.
The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way
From Smallcaps Daily   |   Ad
See how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.
Click to read